(CPRX) Catalyst Pharmaceuticals - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US14888U1016
CPRX EPS (Earnings per Share)
CPRX Revenue
CPRX: Firdapse, Fycompa, Ruzurgi, AGAMREE, Sabril
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company specializing in rare disease treatments in the US. The company has a diverse portfolio of medications, including Firdapse for Lambert-Eaton myasthenic syndrome (LEMS), Fycompa for focal onset seizures and tonic-clonic seizures, Ruzurgi for pediatric LEMS, and AGAMREE, a corticosteroid for Duchenne muscular dystrophy.
The companys strategic partnerships, such as its license agreements with BioMarin Pharmaceutical Inc. and collaboration with Endo Ventures Limited, enhance its product offerings and commercialization capabilities. With a strong focus on rare disease treatments, Catalyst Pharmaceuticals has established itself as a key player in the biotechnology industry.
Analyzing the companys
From a fundamental perspective, Catalyst Pharmaceuticals boasts a market capitalization of $3.044 billion, with a price-to-earnings (P/E) ratio of 15.86 and a forward P/E of 13.46. The companys Return on Equity (RoE) stands at 28.28%, indicating strong profitability.
Combining technical and fundamental insights, we forecast that CPRX will continue its upward trend, driven by its robust product pipeline and strategic partnerships. As the stock price is currently near its 20-day SMA, we anticipate a potential breakout above $26, targeting the 52-week high of $26.31. Conversely, a decline below $23.86 may signal a correction, with support around $22.23. Our forecast is based on the assumption that the companys rare disease focus and partnerships will continue to drive growth, supported by a favorable industry trend.
To validate this forecast, we recommend closely monitoring Catalyst Pharmaceuticals future earnings reports, product approvals, and industry developments, as these factors will significantly impact the stocks performance. A thorough analysis of the companys financials, management team, and competitive landscape will also be essential in determining the stocks long-term potential.
Additional Sources for CPRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
CPRX Stock Overview
Market Cap in USD | 3,045m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2006-11-08 |
CPRX Stock Ratings
Growth Rating | 91.2 |
Fundamental | 92.8 |
Dividend Rating | 0.0 |
Rel. Strength | 70.6 |
Analysts | 4.88 of 5 |
Fair Price Momentum | 28.57 USD |
Fair Price DCF | 35.54 USD |
CPRX Dividends
Currently no dividends paidCPRX Growth Ratios
Growth Correlation 3m | 38.1% |
Growth Correlation 12m | 89.1% |
Growth Correlation 5y | 93.4% |
CAGR 5y | 38.42% |
CAGR/Max DD 5y | 0.85 |
Sharpe Ratio 12m | 0.33 |
Alpha | 45.24 |
Beta | 0.837 |
Volatility | 47.83% |
Current Volume | 1123.4k |
Average Volume 20d | 1116.2k |
As of June 18, 2025, the stock is trading at USD 23.22 with a total of 1,123,446 shares traded.
Over the past week, the price has changed by -11.74%, over one month by -5.72%, over three months by +6.46% and over the past year by +54.80%.
Yes, based on ValueRay´s Fundamental Analyses, Catalyst Pharmaceuticals (NASDAQ:CPRX) is currently (June 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 92.81 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CPRX is around 28.57 USD . This means that CPRX is currently undervalued and has a potential upside of +23.04% (Margin of Safety).
Catalyst Pharmaceuticals has received a consensus analysts rating of 4.88. Therefor, it is recommend to buy CPRX.
- Strong Buy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, CPRX Catalyst Pharmaceuticals will be worth about 32.1 in June 2026. The stock is currently trading at 23.22. This means that the stock has a potential upside of +38.37%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 34 | 46.4% |
Analysts Target Price | 34 | 46.4% |
ValueRay Target Price | 32.1 | 38.4% |